Benchmark International

Benchmarks Exclusive Opportunities

  • Home
  • Opportunities
  • Buyer Profile
  • About
    • About Us
    • From the Chairman
    • Offices
  • Blog
  • Contact
Primary
  • Home
  • Opportunities
  • Buyer Profile
  • About
    • About Us
    • From the Chairman
    • Offices
  • Blog
  • Contact
  • Home
  • About Us
  • Blog
  • Contact Us
  • From the Chairman
  • Offices
  • Opportunities
  • Stats Dashboard
    • Listing Stats
    • Your Listings

Global Communications & Stakeholder Relations Firm – BN000038384

US
500K-2M5M-10M Care, Health & Medical, Professional Services / Consultancy
Add Photos
TEASER
CLIENT CODE: BN000038384
REVENUE/TURNOVER: $8,090,000
EBITDA: $1,229,000
HEADQUARTERS: United States
 
Interested? Contact Us
813-898-2350
pmanry@benchmarkintl.com
Global Communications & Stakeholder Relations Firm – BN000038384

Paul Manry

interested in this opportunity?
Browse My Listings

The company is a global leader in a the highly profitable and in-demand specialty of stakeholder engagement/patient advocacy services to biopharmaceutical and medical device industry clients. For the past 20 years, the company has been providing its clients with comprehensive solutions, including public relations, market shaping, clinical trial support, public policy advocacy, social media, risk management, and overall strategic business consulting.

Key Aspects

  • Average pre-tax income margins of 15.9% from 2017 through 2021
  • Highly skilled personnel with intimate knowledge of the biopharmaceutical & medical device industries, and government processes & regulations
  • Over 22 years in operation, with an industry reputation for excellence and success in comprehensive stakeholder engagement

Opportunities

  • Capitalize on existing opportunities within the biopharmaceutical industry abroad, and further expand services across the healthcare spectrum
  • Expand this company’s proven and scalable model into numerous other global industries requiring comprehensive stakeholder engagement services
  • Leverage the company’s expertise in rare diseases to capitalize on projected growth in this area
  • Implement a strategic marketing campaign, including expansion of the company’s social media footprint, to grow market share and expand into other industries
  • Begin sourcing new projects through Federal requests-for[1]proposals (RFP)

Headquartered

  • United States

Current Markets

  • The company primarily services commercial customers in the biopharmaceutical and medical device industries, located across the globe.

Real Estate

  • The company’s operations are fully remote, with no office space leased or owned by the company.

Shareholder Objectives

  • The company is owned by two shareholders, with one holding a majority position. Both individuals believe it is time to transition to new ownership for their eventual retirement; however, both shareholders are willing to stay with the company for a period of time following the sale to ensure successful transition

You Might Also Like

    AMERICAS HQ

    4030 West Boy Scout Blvd. Suite 500
    Tampa, FL 33609
    +1 813 898 2350
    US@Benchmarkintl.com

    Europe HQ

    101 Park Dr., Milton Park
    Oxfordshire, OX14 4RY
    +44 (0)1865 410 050
    UK@Benchmarkintl.com

    AFRICA HQ

    Ground Floor, Runway 01, Airport Office Park
    Cape Town International Airport, Cape Town, 7525
    +27 21 300 2055
    Africa@Benchmarkintl.com

    Copyright Benchmark International © 2022-2023. All Rights Reserved
    • LinkedIn
    • Twitter
    • Instagram
    • Vimeo
    • YouTube

    Login

    Lost your password?